

February 22, 2010
Shionogi & Co., Ltd.

Shionogi Announces Appointment of Directors, Corporate Officers and Corporate Reorganization

February 22, 2010 -- Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President: Isao Teshirogi; hereafter referred to as “Shionogi”) announced that the Board of Directors Meeting held today informally decided the appointment of directors, which will be officially announced at the 145th Annual General Meeting of Shareholders, scheduled to be held in June, 2010. The Company also announced the following corporate reorganization and appointment of corporate officers as of April 1, 2010.

1. Appointment of Candidates for Director

Candidates for Director (Scheduled in June, 2010)

Board members	Name	Present position
Chairman of the Board, Representative Director	Motozo Shiono	(Reappointed)
President, Representative Director	Isao Teshirogi	(Reappointed)
Director	Sachio Tokaji	(Reappointed)
Director	Yasuhiro Mino	(Reappointed)
Outside Director	Akio Nomura	(Reappointed)
Outside Director	Teppei Mogi	(Reappointed)

*Representative Directors and other Directors are planned to be appointed at the Board of Directors Meeting. It is scheduled to be held on the same day as the Annual General Meeting of Shareholders.

2. Appointment of Corporate Officer (Effective; April 1, 2010)

New	Name	Present position
Executive Officer, Executive General Manager, Pharmaceutical Development Division	Takuko Sawada	Corporate Officer, Executive General Manager, Pharmaceutical Development Division
Corporate Officer, Executive General Manager, Pharmaceutical Research Division	Kohji Hanasaki	General Manager, Discovery Research Laboratories

3. Corporate Reorganization (Effective April 1, 2010)

1) The Discovery Research Laboratories under the Pharmaceutical Research Division will be re-built and separated into the Innovative Drug Discovery Research Laboratories and the Medicinal Research Laboratories.

➤ Innovative Drug Discovery Research Laboratories (Tentative Name):

- Promotes drug target and lead compound research and discovery by making full use of screening and synthetic technology, as well as continuously discovers high-quality drug development candidates

➤ Medicinal Research Laboratories (Tentative Name):

- Handles medical research at all stages which include basic research, discovery research for new drug development candidates, and supportive research for clinical studies and life cycle management of launched products

Also, the Drug Developmental Research Laboratories will be renamed from the Developmental Research Laboratories, which makes contributions to drug discovery and development of the research regarding pharmacokinetics and the toxicity of drug candidates

2) The Supply Chain Management Department (Tentative Name) will be established in order to comprehensively manage supply of finished or purchased products by responding to diversifying manufacturing and distribution and reinforcing foundations for global procurement and supply. In accordance with this establishment, the Purchasing Department will be dissolved and spread between the Supply Chain Management Department and Shionogi General Service & Co. Ltd.

3) The Business Process Improvement Department will be dissolved and absorbed into the Human Resources Department.

4) The current Corporate Planning & Business Development Department will be separated into two new departments: the Corporate Planning & Business Development Department and the Business Development and Licensing Department (Tentative Name).

4. Personnel Reassignments (Effective April 1, 2010)

New (or Continuing) Position	Name	Former Position
Corporate Officer, Executive General Manager, Quality, Safety and Regulatory Affairs Management Division	Hirosato Kondo	Corporate Officer, Executive General Manager, Pharmaceutical Research Division
Corporate Officer, Executive General Manager, Pharmaceutical Research Division	Kohji Hanasaki	General Manager, Discovery Research Laboratories
General Manager, Innovative Drug Discovery Research Laboratories (Tentative Name)	Jun Ishizaki	General Manager, Drug Metabolism & Pharmacokinetics, Development Research Laboratories
General manager, Medicinal Research Laboratories (Tentative Name)	Yoshinori Yamano	General Manager, Infectious Disease Discovery Research Laboratories
General Manager, Drug Developmental Research Laboratories (Tentative Name)	Ikuo Kato	General Manager, Developmental Research Laboratories
General Manager, CMC Development Laboratories	Yasuyuki Kawanishi	General Manager, Production Strategy & Planning Department
General Manager, Chemical Development Center	Norihiko Tanimoto	General Manager, Medical Chemistry 3 Discovery Research Laboratories
General Manager, Kanebashi Plant	Hayao Nakanishi	Deputy General Manager, Process Engineering Unit
General Manager, Production Strategy & Planning Department	Koukichi Kubota	Deputy General Manager, Production Strategy & Planning Department
General Manager, Supply Chain Management Department (Tentative Name)	Kazuhide Masuda	Deputy General Manager, Drug Safety Management Department
General Manager, Distribution Center	Kazuhide Masuda	General Manager, Business Process Improvement Department
General Manager, Corporate Planning & Business Development Department	Ryuichi Kiyama	General Manager, Corporate Planning & Business Development Department
General Manager, Business Development and Licensing Department (Tentative Name)	Hideaki Yamauchi	General Manager, Corporate Planning & Business Development Department

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For further information, contact:

Corporate Communications Department

Shionogi & Co., Ltd.

Telephone: +81-6-6209-7885

Fax: +81-6-6229-9596